Open Interest and Volume Dynamics
The latest data reveals that Sun Pharma’s open interest in derivatives rose sharply to 1,13,584 contracts, up 16.55% from the previous 97,457 contracts. This increase of 16,127 contracts indicates a strong build-up of positions by market participants. Concurrently, the volume stood at 1,12,537 contracts, closely matching the open interest, which suggests active trading and fresh participation rather than mere unwinding of existing positions.
In monetary terms, the futures segment recorded a value of approximately ₹1,39,960 lakhs, while the options segment’s notional value was substantially higher at ₹63,664.99 crores, culminating in a total derivatives value of ₹1,43,080.56 lakhs. This sizeable derivatives turnover underscores the stock’s liquidity and attractiveness among traders.
Price Performance and Technical Indicators
Sun Pharma’s underlying price closed at ₹1,971, just shy of its new peak, reflecting a 1.58% gain on the day. This outperformance is notable against the Pharmaceuticals & Biotechnology sector’s 1.29% rise and the broader Sensex’s 0.97% advance, highlighting relative strength. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained uptrend and positive technical momentum.
However, investor participation measured by delivery volume has shown a decline. The delivery volume on 24 Jul was 12.93 lakh shares, down 13.05% from the five-day average, suggesting some cautiousness among long-term holders despite the bullish price action.
Market Positioning and Potential Directional Bets
The sharp rise in open interest alongside strong volume points to increased speculative interest and possibly fresh directional bets on the stock’s upside. Traders appear to be positioning for continued gains, supported by the stock’s recent breakout to all-time highs and favourable sectoral trends. The large-cap status of Sun Pharma, with a market capitalisation of ₹4,73,268.82 crores, adds to its appeal as a liquid and reliable vehicle for derivatives trading.
Given the substantial increase in options value, it is plausible that market participants are employing a mix of strategies, including call buying and bullish spreads, to capitalise on anticipated upward moves. The futures market activity corroborates this view, with increased long positions likely contributing to the open interest expansion.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Mojo Score Upgrade and Analyst Sentiment
Reflecting the positive technical and fundamental outlook, Sun Pharmaceutical Industries Ltd’s Mojo Score has been upgraded to 74.0, earning a “Buy” grade as of 8 Jun 2026, up from a previous “Hold” rating. This upgrade signals improved confidence in the stock’s medium-term prospects, supported by strong earnings visibility, sector tailwinds, and robust price action.
The large-cap pharmaceutical giant continues to benefit from its diversified product portfolio and expanding global footprint, factors that underpin its steady growth trajectory. The upgrade aligns with the recent surge in derivatives activity, suggesting that institutional and retail investors alike are increasingly bullish on the stock.
Liquidity and Trading Considerations
Liquidity remains a key strength for Sun Pharma, with the stock’s traded value comfortably supporting sizeable trade sizes. Based on 2% of the five-day average traded value, the stock can accommodate trade sizes up to ₹7.57 crores without significant market impact. This liquidity is crucial for derivatives traders looking to enter or exit positions efficiently.
Despite the falling delivery volumes, the overall market interest remains robust, as evidenced by the derivatives turnover and price momentum. Traders should, however, monitor investor participation trends closely, as a sustained decline in delivery volumes could signal profit-booking or cautious sentiment among long-term holders.
Curious about Sun Pharmaceutical Industries Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Outlook and Investor Takeaways
Sun Pharmaceutical Industries Ltd’s recent surge in open interest and volume in the derivatives market, coupled with its breakout to new highs, paints a bullish picture for the near term. The stock’s outperformance relative to its sector and the Sensex, alongside the Mojo Score upgrade, reinforces the positive sentiment.
Investors and traders should consider the stock’s strong technical positioning and liquidity advantages when evaluating entry points. However, the decline in delivery volumes warrants caution, suggesting that some investors may be booking profits or adopting a wait-and-watch stance. Monitoring open interest trends and price action in the coming sessions will be critical to gauge the sustainability of the current rally.
Overall, Sun Pharma remains a compelling large-cap pharmaceutical stock with favourable derivatives market dynamics, making it an attractive candidate for both medium-term investors and active traders seeking exposure to the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
